Dry powders for the inhalation of ciprofloxacin or levofloxacin combined with a mucolytic agent for cystic fibrosis patients

References

• Lay-Son G, Puga A, Astudillo P, et al. Cystic fibrosis in Chilean patients: analysis of 36 common CFTR gene mutations. J Cyst Fibros. 2011;10:66–70.
   PubMed Web of Science ®Google Scholar
• Van Gool K, Norman R, Delatycki MB, et al. Understanding the costs of care for cystic fibrosis: an analysis by age and health state. Value Health. 2013;16:345–355.
   PubMed Web of Science ®Google Scholar
• Garland AL, Walton WG, Coakley RD, et al. Molecular basis for pH-dependent mucosal dehydration in cystic fibrosis airways. Proc Natl Acad Sci USA. 2013;110:15973–15978.
   PubMed Web of Science ®Google Scholar
• Cohen-Cymberknoh M, Shoseyov D, Kerem E. Managing cystic fibrosis: strategies that increase life expectancy and improve quality of life. Am J Respir Crit Care Med. 2011;183:1463–1471.
   PubMed Web of Science ®Google Scholar
• Kaiser J. Personalized medicine. New cystic fibrosis drug offers hope, at a price. Science. 2012;335:645.
   PubMed Web of Science ®Google Scholar
• Mayer M. Lumacaftor-ivacaftor (Orkambi) for cystic fibrosis: behind the 'breakthrough'. Evid Based Med. 2016;21:83–86.
   PubMedGoogle Scholar
• Pezzulo AA, Tang XX, Hoegger MJ, et al. Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. Nature. 2012;487:109–113.
   PubMed Web of Science ®Google Scholar
• Elborn JS, Henig NR. Optimal airway antimicrobial therapy for cystic fibrosis: the role of inhaled aztreonam lysine. Expert Opin Pharmacother. 2010;11:1373–1385.
   PubMed Web of Science ®Google Scholar
• Cipolla D, Chan HK. Inhaled antibiotics to treat lung infection. Pharm Pat Anal. 2013;2:647–663.
   PubMedGoogle Scholar
• Buttini F, Rossi I, Di Cuia M, et al. Combinations of colistin solutions and nebulisers for lung infection management in cystic fibrosis patients. Int J Pharm. 2016;502:242–248.
   PubMed Web of Science ®Google Scholar
• Balducci AG, Bettini R, Colombo P, et al. Drug delivery strategies for pulmonary administration of antibiotics. In: Nokhodchi A, Martin GP, editors. Pulmonary drug delivery: advances and challenges. 1st ed. Chichester, UK: John Wiley & Sons, Ltd; 2015. p. 241–262.
   Google Scholar
• Hodson ME, Butland RJA, Roberts CM, et al. Oral ciprofloxacin compared with conventional intravenous treatment for pseudomonas-aeruginosa infection in adults with cystic-fibrosis. Lancet. 1987;1:235–237.
   PubMed Web of Science ®Google Scholar
• Bosso JA, Black PG, Matsen JM. Ciprofloxacin versus tobramycin plus azlocillin in pulmonary exacerbations in adult patients with cystic fibrosis. Am J Med. 1987;82:180–184.
   PubMed Web of Science ®Google Scholar
• Geller DE, Flume PA, Staab D, et al. Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. Am J Respir Crit Care Med. 2011;183:1510–1516.
   PubMed Web of Science ®Google Scholar
• Stass H, Weimann B, Nagelschmitz J, et al. Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study. Clin Ther. 2013;35:1571–1581.
   PubMed Web of Science ®Google Scholar
• Geller DE, Flume PA, Griffith DC, et al. Pharmacokinetics and safety of MP-376 (levofloxacin inhalation solution) in cystic fibrosis subjects. Antimicrob Agents Chemother. 2011;55:2636–2640.
   PubMed Web of Science ®Google Scholar
• Azoicai D, Antoniu SA. MP-376 (Aeroquin) for chronic Pseudomonas aeruginosa infections. Expert Opin Investig Drugs. 2013;22:267–276.
   PubMed Web of Science ®Google Scholar
• Gaspar MC, Grégoire N, Sousa JJS, et al. Pulmonary pharmacokinetics of levofloxacin in rats after aerosolization of immediate-release chitosan or sustained-release PLGA microspheres. Eur J Pharm Sci. 2016;93:184–191.
   PubMed Web of Science ®Google Scholar
• Chamseddin C, Jira TH. Comparison of the chromatographic behavior of levofloxacin, ciprofloxacin and moxifloxacin on various HPLC phases. Pharmazie. 2011;66:244–248.
   PubMed Web of Science ®Google Scholar
• Yang Y, Tsifansky MD, Wu CJ, et al. Inhalable antibiotic delivery using a dry powder co-delivering recombinant deoxyribonuclease and ciprofloxacin for treatment of cystic fibrosis. Pharm Res. 2010;27:151–160.
   PubMed Web of Science ®Google Scholar
• Frick A, Möller H, Wirbitzki E. Biopharmaceutical characterization of oral immediate release drug products. In vitro/in vivo comparison of phenoxymethylpenicillin potassium, glimepiride and levofloxacin. Eur J Pharm Biopharm. 1998;46:305–311.
   PubMed Web of Science ®Google Scholar
• Frederiksen B, Pressler T, Hansen A, et al. Effect of aerosolized rhDNase (Pulmozyme) on pulmonary colonization in patients with cystic fibrosis. Acta Paediatr. 2006;95:1070–1074.
   PubMed Web of Science ®Google Scholar
• Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med. 2006;354:229–240.
   PubMed Web of Science ®Google Scholar
• El-Feky MA, El-Rehewy MS, Hassan MA, et al. Effect of ciprofloxacin and N-acetylcysteine on bacterial adherence and biofilm formation on ureteral stent surfaces. Pol J Microbiol. 2009;58:261–267.
   PubMed Web of Science ®Google Scholar
• Adi H, Young PM, Chan HK, et al. Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease. Eur J Pharm Sci. 2010;40:239–247.
   PubMed Web of Science ®Google Scholar
• Seville PC, Li HY, Learoyd TP. Spray-dried powders for pulmonary drug delivery. Crit Rev Ther Drug Carrier Syst. 2007;24:307–360.
   PubMed Web of Science ®Google Scholar
• Son YJ, Horng M, Copley M, et al. Optimization of an in vitro dissolution test method for inhalation formulations. Dissolution Technol. 2010;6:6–13.
   Google Scholar
• Bensikaddour H, Snoussi K, Lins L, et al. Interactions of ciprofloxacin with DPPC and DPPG: fluorescence anisotropy, ATR-FTIR and 31P NMR spectroscopies and conformational analysis. Biochim Biophys Acta. 2008;1778:2535–2543.
   PubMed Web of Science ®Google Scholar
• Ong HX, Traini D, Bebawy M, et al. Ciprofloxacin is actively transported across bronchial lung epithelial cells using a Calu-3 air interface cell model. Antimicrob Agents Chemother. 2013;57:2535–2540.
   PubMed Web of Science ®Google Scholar
• Varanda F, Pratas de Melo MJ, Caço AI, et al. Solubility of antibiotics in different solvents. 1. hydrochloride forms of tetracycline, moxifloxacin, and ciprofloxacin. Ind Eng Chem Res. 2006;45:6368–6374.
   Web of Science ®Google Scholar
• Klingler C, Muller BW, Steckel H. Insulin-micro- and nanoparticles for pulmonary delivery. Int J Pharm. 2009;377:173–179.
   PubMed Web of Science ®Google Scholar
• Westerman EM, De Boer AH, Le Brun PPH, et al. Dry powder inhalation of colistin in cystic fibrosis patients: a single dose pilot study. J Cyst Fibros. 2007;6:284–292.
   PubMed Web of Science ®Google Scholar
• Italian.merryapi.com [Internet]. Cloridrato cas della ciprofloxacina nessun antibiotico 86393-32-0 ed agenti antimicrobici per farmaceutico; 2017 [cited 2017 Jan 26]; Available from: http://italian.merryapi.com/quality-5734308-ciprofloxacin-hydrochloride-cas-no-86393-32-0-antibiotic-and-antimicrobial-agents-for-pharmaceutical.
   Google Scholar
• Dorofeev VL, Arzamastsev AP, Veselova OM. Melting point determination for the analysis of drugs of the fluoroquinolone group. Pharm Chem J. 2004;38:333–335.
   Google Scholar
• Biotechnology SC Technical Information [Internet]; 2015. [cited 2015 Apr 30]; Available from: https://www.scbt.com/scbt/it/product/n-acetyl-l-cysteine-616-91-1.
   Google Scholar
• Gorman EM, Samas B, Munson EJ. Understanding the dehydration of levofloxacin hemihydrate. J Pharm Sci. 2012;101:3319–3330.
   PubMed Web of Science ®Google Scholar
• Hoang Thi TH, Chai F, Lepretre S, et al. Bone implants modified with cyclodextrin: study of drug release in bulk fluid and into agarose gel. Int J Pharm. 2010;400:74–85.
   PubMed Web of Science ®Google Scholar
• Pubchem.ncbi.nlm.nih.gov [Internet]. N-Acetyl-L-cysteine | C5H9NO3S – PubChem; 2017 [cited 2017 Jan 26]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/N-Acetyl-L-cysteine#section=Color.
   Google Scholar
• Sahoo S, Chakraborti CK, Mishra SC, et al. FTIR and XRD investigations of some fluoroquinolones. Int J Pharm Pharm Sci. 2011;3:165–170.
   Google Scholar
• Kumar G, Sharma S, Shafiq N, et al. Optimization, in vitro-in vivo evaluation, and short-term tolerability of novel levofloxacin-loaded PLGA nanoparticle formulation. J Pharm Sci. 2012;101:2165–2176.
   PubMed Web of Science ®Google Scholar
• Gulsun T, Budak C, Vural I, et al. Preparation and characterization of nimesulide containing nanocrystal formulations. Pharm Dev Technol. 2013;18:653–659.
   PubMed Web of Science ®Google Scholar
• Gordon MS. inventor; Inhale Therapeutic Systems, assignee. Processes for spray drying hydrophobic drugs in organic solvent suspensions. United States patent US 5976574; 1999 Nov 2.
   Google Scholar
• Buttini F, Hannon J, Saavedra K, et al. Accessorized DPI: a shortcut towards flexibility and patient adaptability in dry powder inhalation. Pharm Res. 2016;33:3012–3020.
   PubMed Web of Science ®Google Scholar
• Belotti S, Rossi A, Colombo P, et al. Spray-dried amikacin sulphate powder for inhalation in cystic fibrosis patients: the role of ethanol in particle formation. Eur J Pharm Biopharm. 2015;93:165–172.
   PubMed Web of Science ®Google Scholar
• Belotti S, Rossi A, Colombo P, et al. Spray dried amikacin powder for inhalation in cystic fibrosis patients: a quality by design approach for product construction. Int J Pharm. 2014;471:507–515.
   PubMed Web of Science ®Google Scholar
• Sweeney LG, Wang Z, Loebenberg R, et al. Spray-freeze-dried liposomal ciprofloxacin powder for inhaled aerosol drug delivery. Int J Pharm. 2005;305:180–185.
   PubMed Web of Science ®Google Scholar
• Gaspar MC, Sousa JJ, Pais AA, et al. Optimization of levofloxacin-loaded crosslinked chitosan microspheres for inhaled aerosol therapy. Eur J Pharm Biopharm. 2015;96:65–75.
   PubMed Web of Science ®Google Scholar
• Martinelli F, Balducci AG, Rossi A, et al. ‘Pierce and inhale’ design in capsule based dry powder inhalers: effect of capsule piercing and motion on aerodynamic performance of drugs. Int J Pharm. 2015;487:197–204.
   PubMed Web of Science ®Google Scholar
• Ong HX, Traini D, Young PM. Pharmaceutical applications of the Calu-3 lung epithelia cell line. Expert Opin Drug Deliv. 2013;10:1287–1302.
   PubMed Web of Science ®Google Scholar
• Borchard G, Cassara ML, Roemele PE, et al. Transport and local metabolism of budesonide and fluticasone propionate in a human bronchial epithelial cell line (Calu-3). J Pharm Sci. 2002;91:1561–1567.
   PubMed Web of Science ®Google Scholar
• Grainger CI, Greenwell LL, Martin GP, et al. The permeability of large molecular weight solutes following particle delivery to air-interfaced cells that model the respiratory mucosa. Eur J Pharm Biopharm. 2009;71:318–324.
   PubMed Web of Science ®Google Scholar
• Foster KA, Avery ML, Yazdanian M, et al. Characterization of the Calu-3 cell line as a tool to screen pulmonary drug delivery. Int J Pharm. 2000;208:1–11.
   PubMed Web of Science ®Google Scholar